Report Summary
Bangladesh Pharmaceuticals and Healthcare Report Q2 2010
Of the 15 key markets surveyed in BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BERs), Bangladesh can be found at the bottom of the table. For Q210, the country’s pharmaceutical rating stands at 38.5. Despite Bangladesh’s recent decline, we expect its position to improve over the medium term as a result of rising population numbers, economic improvements and efforts made by domestic firms to expand both their products portfolios and overseas markets. We therefore envisage that sales of pharmaceutical products will increase over the next 10 years, with sales of prescription drugs and over-the-counter (OTC) medications expected to grow from US$1.13bn in 2009 to US$3.44bn in 2019, representing a compound annual growth rates (CAGR) in local currency and US dollar terms of 14.6% and 11.81% respectively. It has emerged that a new pharmaceutical regulatory body will be established to replace Bangladesh’s Directorate General of Drug Administration (DDA). BMI is therefore poised to upgrade Bangladesh’s scores for ‘policy/reimbursement’, and ‘approvals process’ in our BERs, following the creation of the Directorate General of Drug Administration (DGDA).The new medicine regulator is seeking to employ 1,000 staff in addition to those it will retain from the former regulator and is set to be fully operational within a year. Meanwhile, a global flagship report published by the United Nations Children’s Fund (UNICEF) on infant mortality rates has revealed that the incidence of infant mortality in Bangladesh has halved since 1990. Since 2008, infant mortality levels have decreased to 43 per 1,000 births (from 103), while the mortality rates of children under the age of five has also decreased from 149 to 54 per 1,000 births over the 18-year period. During 2008, local pharmaceutical companies exported medicines with a value of US$45.35mn. The number of destinations for exports has risen from 37 to 72 countries during the period. However, despite the growth in export revenue, the import of pharmaceuticals currently exceeds the level of exports. In 2008, pharmaceutical products worth US$55.52mn were imported into Bangladesh as opposed to US$47.34mn in 2007. By 2014, BMI expects exports to have overtaken imports, reaching a value of US$226.75mn and US$166.56mn, respectively.
Business Monitor International
With regard to the domestic market, a report published by Intercontinental Marketing Services (IMS) in August 2009 suggests that sales by local pharmaceutical manufacturers increased by 21% over the April to June period, marking a rise of 19% over the first three months of the year. Factors that have helped boost growth include developed manufacturing processes, newer investments in the sector and improved marketing strategies. Opsonin was the best performer, with a 51% increase in sales; followed by Eskayef with 42% and Drug International Limited with 39%, over the prescribed period.
Pharmaceuticals
Executive Summary
SWOT Analysis
Bangladesh Pharmaceuticals And Healthcare Industry SWOT
Bangladesh Political SWOT
Bangladesh Economic SWOT
Bangladesh Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q210
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Table: Steps Required To Establish Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence (DML)
Counterfeit Drugs
Intellectual Property
Pricing And Reimbursement Regime
Industry Trends And Developments
Epidemiology
Healthcare Sector
Contract Manufacturing
Research And Development
Table: Suggestions Made By University Of Dhaka’s Faculty Of Pharmacy To Improve Pharmaceutical Research Standards
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Macroeconomic Activity
Bangladesh - Economic Activity, 2007-2013
Prescription Drug Market Forecast
Patented Product Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecasts
Competitive Landscape
Recent Activities By Foreign Companies
Company Profiles
Indigenous Companies
Eskayef Bangladesh
Square Pharmaceuticals
Renata
Beximco Pharmaceuticals
Country Snapshot: Bangladesh Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2001-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2010 (US$)
Table: Average Annual Manufacturing Wages
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Forecast Tables
